U.S. markets close in 3 hours 52 minutes
  • S&P 500

    4,059.16
    -17.41 (-0.43%)
     
  • Dow 30

    34,331.11
    -63.90 (-0.19%)
     
  • Nasdaq

    11,403.66
    -78.79 (-0.69%)
     
  • Russell 2000

    1,883.35
    +1.67 (+0.09%)
     
  • Crude Oil

    81.48
    +0.26 (+0.32%)
     
  • Gold

    1,809.30
    -5.90 (-0.33%)
     
  • Silver

    23.41
    +0.56 (+2.47%)
     
  • EUR/USD

    1.0522
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    3.5760
    +0.0470 (+1.33%)
     
  • GBP/USD

    1.2289
    +0.0033 (+0.27%)
     
  • USD/JPY

    134.8640
    -0.4420 (-0.33%)
     
  • BTC-USD

    16,941.09
    -36.58 (-0.22%)
     
  • CMC Crypto 200

    402.00
    +0.58 (+0.14%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

  • Zymeworks Inc (NASDAQ: ZYMEpresented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors.

  • The data were presented at the European Society for Medical Oncology Annual Congress.

  • A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy.

  • Also Read: Zymeworks Turns Down All Blue's Hostile Bid.

  • At the time of the analysis, the maximum tolerated dose had not yet been reached.

  • In the trial, zanidatamab zovodotin was shown to have a manageable safety profile, with the majority of adverse events being mild or moderate.

  • In patients with HER2-positive cancers treated with zanidatamab zovodotin at 2.5 mg/kg Q3W, the confirmed objective response rate was 31%, and the disease control rate was 72%.

  • The Phase 1 trial continues to enroll patients to study safety. The company expects to present the results of this dosing regimen at a medical meeting in 2023.

  • Price Action: ZYME shares are up 0.20% at $4.95 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.